People: Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

26 May 2017
Change (% chg)

$0.09 (+0.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sebree, Terri 

Ms. Terri B. Sebree is the President of the company. Prior to joining the company, Ms. Sebree served as business consultant from May 2014 to October 2014. She has more than 30 years of executive, development and operational experience in the pharmaceutical industry, particularly in central nervous system product development including epilepsy and pain. Ms. Sebree founded and served as president of NuPathe, a specialty pharmaceutical company, from February 2005 until April 2014, where she led the effort to develop, achieve regulatory approval for and complete manufacturing of the company's lead product, Zecuity, a transdermal patch for migraines. Prior to founding NuPathe, Ms. Sebree served as senior vice president, development of Auxilium, a specialty pharmaceutical company, where she led the development and approval program of Testim, a testosterone gel. Prior to joining Auxilium, she served as executive vice president, U.S. Operations at IBAH, Inc., a contract research organization. Prior to that, she served in a variety of management roles with Abbott Laboratories Inc., a global healthcare company, for over nine years. She currently serves on the board of directors of Serodus ASA, a publicly traded company on the Oslo Stock Exchange. Ms. Sebree holds a B.S. from Texas A&M University.

Basic Compensation

Total Annual Compensation, USD 98,461
Restricted Stock Award, USD 400,198
Long-Term Incentive Plans, USD --
All Other, USD 117,264
Fiscal Year Total, USD 615,923

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --